LDH Inhibitors as Treatment for Fibrotic Disorders

One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.


URV Reference Number: 6-2259
Patent Information:
Title Country Patent No. Issued Date
LDH Inhibitors as Treatment for Fibrosis and for Fibrotic-Related Disorders United States 9,750,761 9/5/2017
For Information, Contact:
Blaze Pharoah
Licensing Manager
University of Rochester
Robert Kottmann
Patricia Sime
Richard Phipps